Tyra Biosciences (NASDAQ:TYRA) Hits New 12-Month Low – Time to Sell?

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $11.79 and last traded at $11.77, with a volume of 52140 shares. The stock had previously closed at $12.20.

Analyst Ratings Changes

Several equities research analysts recently weighed in on TYRA shares. UBS Group assumed coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, February 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $30.50.

Tyra Biosciences Price Performance

The firm has a market cap of $593.07 million, a price-to-earnings ratio of -7.28 and a beta of 1.05. The firm’s 50 day moving average price is $14.32 and its 200-day moving average price is $18.01.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the transaction, the director now directly owns 3,707,420 shares in the company, valued at $60,653,391.20. The trade was a 0.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders have sold 21,998 shares of company stock worth $344,818. 15.40% of the stock is currently owned by company insiders.

Institutional Trading of Tyra Biosciences

A number of large investors have recently bought and sold shares of TYRA. Janus Henderson Group PLC bought a new position in shares of Tyra Biosciences in the third quarter valued at approximately $24,994,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Tyra Biosciences in the 3rd quarter valued at $593,000. JPMorgan Chase & Co. raised its position in Tyra Biosciences by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after purchasing an additional 3,896 shares during the last quarter. Barclays PLC grew its holdings in shares of Tyra Biosciences by 200.5% during the third quarter. Barclays PLC now owns 37,625 shares of the company’s stock worth $884,000 after purchasing an additional 25,106 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Tyra Biosciences by 2.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock valued at $4,085,000 after buying an additional 3,792 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.